Literature DB >> 23986449

Factor V activator from Daboia russelli russelli venom destabilizes β-amyloid aggregate, the hallmark of Alzheimer disease.

Payel Bhattacharjee1, Debasish Bhattacharyya.   

Abstract

Formation of plaque by fibrils of β-amyloid (Aβ) peptide in the brain is the characteristic feature of Alzheimer disease (AD). Inhibition of the process of aggregate formation from Aβ-monomer and destabilization of the aggregate could be useful for prevention and propagation of the disease respectively. Russell's viper venom (RVV) contains protein(s) that destabilize Aβ aggregates as revealed from the thioflavin T assay. The active component was identified as factor V activator (RVV-V). Among the possible mechanisms of destabilization, RVV-V-mediated proteolysis was ruled out from mass spectrometric data and the thioflavin T assay. The alternate hypothesis that small peptides derived from RVV-V destabilize the aggregate is better supported by experimental results. Six small peptides were synthesized using RVV-V as the template, and three unrelated peptides were synthesized to serve as controls. Destabilization of Aβ aggregate by these peptides was studied using spectrofluorometric assays, atomic force microscopy, transmission electron microscopy, and confocal microscopy. Among the peptides, CTNIF and the mixture of the six peptides were most potent in converting the aggregates to the monomeric state and thus, preventing cytotoxicity in SH-SY5Y human neuroblastoma cells. The control peptides failed to show similar effects. Moreover, some of these peptides are stable in blood for 24 h. Therefore, these venom-derived peptides offer an encouraging opportunity to prevent amyloidosis and may provide information to combat AD.

Entities:  

Keywords:  Aggregation; Amyloid; Neurodegenerative Diseases; Peptides; Russell's Viper Venom Factor V Activator; Toxins

Mesh:

Substances:

Year:  2013        PMID: 23986449      PMCID: PMC3798527          DOI: 10.1074/jbc.M113.511410

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide.

Authors:  T H Huang; D S Yang; N P Plaskos; S Go; C M Yip; P E Fraser; A Chakrabartty
Journal:  J Mol Biol       Date:  2000-03-17       Impact factor: 5.469

2.  Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.

Authors:  Cyrus K Bett; Johnpeter N Ngunjiri; Wilson K Serem; Krystal R Fontenot; Robert P Hammer; Robin L McCarley; Jayne C Garno
Journal:  ACS Chem Neurosci       Date:  2010-07-08       Impact factor: 4.418

3.  Snake venom proteases that activate blood-coagulation factor V.

Authors:  W Kisiel; W M Canfield
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences.

Authors:  F Tokunaga; K Nagasawa; S Tamura; T Miyata; S Iwanaga; W Kisiel
Journal:  J Biol Chem       Date:  1988-11-25       Impact factor: 5.157

5.  Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation.

Authors:  Jason E Gestwicki; Gerald R Crabtree; Isabella A Graef
Journal:  Science       Date:  2004-10-29       Impact factor: 47.728

6.  Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease.

Authors:  Céline Adessi; Marie-José Frossard; Christophe Boissard; Santiago Fraga; Sylvain Bieler; Thomas Ruckle; Francis Vilbois; Sandra M Robinson; Manfred Mutter; William A Banks; Claudio Soto
Journal:  J Biol Chem       Date:  2003-02-10       Impact factor: 5.157

7.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

8.  Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis.

Authors:  D J Gordon; R Tappe; S C Meredith
Journal:  J Pept Res       Date:  2002-07

9.  The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides.

Authors:  M S Shearman; S R Hawtin; V J Tailor
Journal:  J Neurochem       Date:  1995-07       Impact factor: 5.372

10.  Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways.

Authors:  Gal Bitan; Marina D Kirkitadze; Aleksey Lomakin; Sabrina S Vollers; George B Benedek; David B Teplow
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-27       Impact factor: 11.205

View more
  5 in total

Review 1.  Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases.

Authors:  Jessica M de Souza; Bruno D C Goncalves; Marcus V Gomez; Luciene B Vieira; Fabiola M Ribeiro
Journal:  Front Pharmacol       Date:  2018-02-23       Impact factor: 5.810

2.  Targeted Sequencing of Alzheimer Disease Genes in African Americans Implicates Novel Risk Variants.

Authors:  Mark W Logue; Daniel Lancour; John Farrell; Irina Simkina; M Daniele Fallin; Kathryn L Lunetta; Lindsay A Farrer
Journal:  Front Neurosci       Date:  2018-08-27       Impact factor: 4.677

3.  L-amino acid oxidase from Bothrops atrox snake venom triggers autophagy, apoptosis and necrosis in normal human keratinocytes.

Authors:  Fernanda Costal-Oliveira; Stephanie Stransky; Clara Guerra-Duarte; Dayane L Naves de Souza; Dan E Vivas-Ruiz; Armando Yarlequé; Eladio Flores Sanchez; Carlos Chávez-Olórtegui; Vania M M Braga
Journal:  Sci Rep       Date:  2019-01-28       Impact factor: 4.379

4.  An Enzyme from Aristolochia indica Destabilizes Fibrin-β Amyloid Co-Aggregate: Implication in Cerebrovascular Diseases.

Authors:  Payel Bhattacharjee; Debasish Bhattacharyya
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

5.  Proteomic Analysis of Preoperative CSF Reveals Risk Biomarkers of Postoperative Delirium.

Authors:  Yongzheng Han; Wei Chen; Yanan Song; Yi Yuan; Zhengqian Li; Yang Zhou; Taotao Liu; Dengyang Han; Xinning Mi; Min Li; Geng Wang; Lijun Zhong; Juntuo Zhou; Xiangyang Guo
Journal:  Front Psychiatry       Date:  2020-03-04       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.